0 Avaliações

ID

30996

Descrição

This ODM file contains documentation of Non-Serious Adverse Events. To be checked for (and added if neccessary) at Sessions 1 and 2 (Day -1), Early Withdrawal and Follow-Up. Study ID: 109710 Clinical Study ID: DAN109710 Study Title: A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01039454 https://clinicaltrials.gov/ct2/show/NCT01039454 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK598809 Trade Name: Study Indication: Substance Dependence Brief Summary: This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese. Recent research has shown that some kinds of overeating may be linked to a brain chemical called dopamine. There is some evidence that blocking the action of this chemical in animals can reduce food intake, particularly of foods that are high in fat and sugar. The purpose of this study is to find out if this compound (which blocks the effects of dopamine) has the same effect in overweight or obese people, as it does in animals.

Link

https://clinicaltrials.gov/ct2/show/NCT01039454

Palavras-chave

  1. 29.06.18 29.06.18 - Sarah Riepenhausen
  2. 09.07.18 09.07.18 - Sarah Riepenhausen
Titular dos direitos

GlaxoSmithKline

Transferido a

9. Juli 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :


    Sem comentários

    Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

    Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454

    Non-Serious Adverse Events

    Administrative Data
    Descrição

    Administrative Data

    Alias
    UMLS CUI-1
    C1320722 (Administrative documentation)
    SNOMED
    405624007
    Subject Identifier
    Descrição

    Subject Identifier

    Tipo de dados

    text

    Alias
    UMLS CUI [1]
    C2348585 (Clinical Trial Subject Unique Identifier)
    Non-Serious Adverse Events
    Descrição

    Non-Serious Adverse Events

    Alias
    UMLS CUI-1
    C1518404 (Non-serious Adverse Event)
    Did the subject experience any non-serious adverse events during the study?
    Descrição

    If Yes, record details below in the following questions of this itemgroup (fill out the set of questions for each non-serious adverse event). Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. Examples of an AE include: Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. New condition(s) detected or diagnosed after investigational product administration even though it may have been present prior to the start of the study. Signs, symptoms, or the clinical sequelae of a suspected interaction. Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concomitant medication (overdose per se should not be reported as an AE/SAE). Examples of an AE do NOT include a/an: Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE. Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen. The disease/disorder being studied, or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject’s condition. For GSK clinical studies, AEs may include pre- or post-treatment events that occur as a result of protocol-mandated procedures (i.e., invasive procedures, modification of subject’s previous therapeutic regimen). See protocol for clarification. IF THIS EVENT MEETS THE DEFINITION OF SERIOUS, COMPLETE THE SERIOUS ADVERSE EVENT SECTION INSTEAD

    Tipo de dados

    text

    Alias
    UMLS CUI [1]
    C1518404 (Non-serious Adverse Event)
    Diagnosis only (if known, otherwise Sign/Symptom)
    Descrição

    Ensure that no medical or investigational procedures are captured on Non-Serious Adverse Events pages. If a diagnosis subsequently becomes available, then this should be entered and the sign or symptom crossed out, initialled and dated by the investigator. Non-serious adverse event terms should be reviewed for potential SAEs per protocol. If this non-serious event progresses to serious, put a line through the Non-Serious AE record and transcribe the details onto the SAE form.

    Tipo de dados

    text

    Alias
    UMLS CUI [1]
    C1518404 (Non-serious Adverse Event)
    Record the start date of the first occurrence of the AE.
    Descrição

    Start dates must be provided for the reporting of adverse event data. If the exact date is not known, liaise with the investigator to ensure that a best estimate is provided.

    Tipo de dados

    date

    Alias
    UMLS CUI [1,1]
    C1518404 (Non-serious Adverse Event)
    UMLS CUI [1,2]
    C2697888 (Adverse Event Start Date)
    Record the start time of the AE.
    Descrição

    Start Time Non-Serious Adverse Event

    Tipo de dados

    time

    Alias
    UMLS CUI [1,1]
    C1518404 (Non-serious Adverse Event)
    UMLS CUI [1,2]
    C2697889 (Adverse Event Start Time)
    Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
    Descrição

    Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with normal everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).

    Tipo de dados

    text

    Alias
    UMLS CUI [1,1]
    C0518690 (Symptom intensity)
    UMLS CUI [1,2]
    C1518404 (Non-serious Adverse Event)
    Outcome
    Descrição

    All AEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the AE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the AE was ongoing at the time of death, but was not the cause of death.

    Tipo de dados

    integer

    Alias
    UMLS CUI [1,1]
    C1705586 (Adverse Event Outcome)
    UMLS CUI [1,2]
    C1518404 (Non-serious Adverse Event)
    Action Taken with Investigational Prodcut(s) as a result of the Non-Serious AE
    Descrição

    Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing).

    Tipo de dados

    text

    Alias
    UMLS CUI [1,1]
    C1704758 (Action Taken with Study Treatment)
    UMLS CUI [1,2]
    C1518404 (Non-serious Adverse Event)
    Record the end date.
    Descrição

    This is the date the AE Recovered/Resolved. If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the AE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.

    Tipo de dados

    date

    Alias
    UMLS CUI [1,1]
    C2697886 (Adverse Event End Date)
    UMLS CUI [1,2]
    C1518404 (Non-serious Adverse Event)
    Did the subject withdraw from study as a result fo this AE?
    Descrição

    Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If the subject was withdrawn from the study due to an adverse event, confirm that the following variables are consistent for the adverse event which resulted in withdrawal: If investigational product was permanently withdrawn due to an adverse event: ‘Primary Reason for Withdrawal’ on the Study Conclusion page is recorded as ‘Adverse Event’ If the subject was withdrawn from the study for an adverse event: ‘Withdrawal’ on the Non-Serious Adverse Events page is recorded as ‘Yes’, ‘Action Taken with Investigational Product(s) as a Result of the Non-Serious AE’ on the Non-Serious Adverse Events page is recorded as ‘Investigational Product Withdrawn’.

    Tipo de dados

    text

    Alias
    UMLS CUI [1,1]
    C1710677 (Withdrawal by Subject)
    UMLS CUI [1,2]
    C1518404 (Non-serious Adverse Event)
    Record the end time of the AE.
    Descrição

    End Time Non-Serious Adverse Event

    Tipo de dados

    time

    Alias
    UMLS CUI [1,1]
    C1518404 (Non-serious Adverse Event)
    UMLS CUI [1,2]
    C2826658 (Adverse Event End Time)
    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    Descrição

    It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

    Tipo de dados

    text

    Alias
    UMLS CUI [1,1]
    C0304229 (Experimental drug)
    UMLS CUI [1,2]
    C0085978 (Causations)
    UMLS CUI [1,3]
    C1518404 (Non-serious Adverse Event)
    Frequency
    Descrição

    Intermittent should be used if the subject experiences the same AE on multiple occasions over a period of time (e.g., dizziness). In these circumstances, the start date will be the start date of the first episode and the end date will be the date of resolution.

    Tipo de dados

    integer

    Alias
    UMLS CUI [1,1]
    C1518404 (Non-serious Adverse Event)
    UMLS CUI [1,2]
    C0439603 (Frequencies (time pattern))
    SNOMED
    272123002
    LOINC
    LP130485-8

    Similar models

    Non-Serious Adverse Events

    Name
    Tipo
    Description | Question | Decode (Coded Value)
    Tipo de dados
    Alias
    Item Group
    Administrative Data
    C1320722 (UMLS CUI-1)
    Subject Identifier
    Item
    Subject Identifier
    text
    C2348585 (UMLS CUI [1])
    Item Group
    Non-Serious Adverse Events
    C1518404 (UMLS CUI-1)
    Item
    Did the subject experience any non-serious adverse events during the study?
    text
    C1518404 (UMLS CUI [1])
    Code List
    Did the subject experience any non-serious adverse events during the study?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Event
    Item
    Diagnosis only (if known, otherwise Sign/Symptom)
    text
    C1518404 (UMLS CUI [1])
    Start Date Non-Serious Adverse Event
    Item
    Record the start date of the first occurrence of the AE.
    date
    C1518404 (UMLS CUI [1,1])
    C2697888 (UMLS CUI [1,2])
    Start Time Non-Serious Adverse Event
    Item
    Record the start time of the AE.
    time
    C1518404 (UMLS CUI [1,1])
    C2697889 (UMLS CUI [1,2])
    Item
    Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
    text
    C0518690 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Code List
    Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
    CL Item
    Mild (1)
    (Comment:en)
    CL Item
    Moderate (2)
    (Comment:en)
    CL Item
    Severe (3)
    (Comment:en)
    CL Item
    Not applicable (X)
    (Comment:en)
    Item
    Outcome
    integer
    C1705586 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Code List
    Outcome
    CL Item
    Recovered/Resolved (1)
    CL Item
    Recovering/Resolving (2)
    CL Item
    Not Recovered/Not resolved (3)
    CL Item
    Recovered/Resolved with Sequelae (4)
    Item
    Action Taken with Investigational Prodcut(s) as a result of the Non-Serious AE
    text
    C1704758 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Code List
    Action Taken with Investigational Prodcut(s) as a result of the Non-Serious AE
    CL Item
    Investigational Product(s) withdrawn (1)
    CL Item
    Dose reduced (2)
    CL Item
    Dose increased (3)
    CL Item
    Dose not changed (4)
    CL Item
    Dose interrupted (5)
    CL Item
    Not applicable (X)
    End Date Non-serious Adverse Event
    Item
    Record the end date.
    date
    C2697886 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Item
    Did the subject withdraw from study as a result fo this AE?
    text
    C1710677 (UMLS CUI [1,1])
    C1518404 (UMLS CUI [1,2])
    Code List
    Did the subject withdraw from study as a result fo this AE?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    End Time Non-Serious Adverse Event
    Item
    Record the end time of the AE.
    time
    C1518404 (UMLS CUI [1,1])
    C2826658 (UMLS CUI [1,2])
    Item
    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    text
    C0304229 (UMLS CUI [1,1])
    C0085978 (UMLS CUI [1,2])
    C1518404 (UMLS CUI [1,3])
    Code List
    Is there a reasonable possibility that the AE may have been caused by the investigational product?
    CL Item
    Yes (Y)
    CL Item
    No (N)
    Item
    Frequency
    integer
    C1518404 (UMLS CUI [1,1])
    C0439603 (UMLS CUI [1,2])
    CL Item
    Single Episode (1)
    CL Item
    Intermittent (2)

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial